Dow Drops More Than 1%; Nio Stock Declines Following Q2 Earnings Report
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 02 2025
0mins
Should l Buy UTHR?
Source: Benzinga
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones falling over 1%, while the NASDAQ and S&P 500 also experienced significant drops. Notable movements included a 2% decrease in NIO shares following disappointing quarterly results, despite a year-over-year revenue increase.
Sector and Commodity Updates: Consumer staples saw a slight increase, while information technology stocks fell. In commodities, oil and gold prices rose, and European and Asian markets mostly closed lower, reflecting a broader trend of declining equities globally.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to fall
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 596.760
Low
423.00
Averages
534.50
High
645.00
Current: 596.760
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Results: United Therapeutics highlighted significant outcomes from two Phase III trials in its Q1 earnings report, achieving a p-value of less than 0.0001, indicating substantial therapeutic potential in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), which is expected to drive revenue growth from $3 billion to $4 billion.
- Revenue Performance: The company reported total revenue of $782 million for Q1 2026, facing challenges from severe winter weather and pharmacy operational issues that slowed starts; however, management remains confident in returning to sequential growth and sustaining double-digit growth in the near term.
- New Product Development: The introduction of the inhaled formulation of ralinepag (RALDPI) is anticipated to treat tens of thousands of patients across PAH, ILD, IPF, and PPF, further expanding market share and enhancing revenue potential.
- Regulatory Progress: Management plans to file a supplemental new drug application for IPF by the end of summer and expects a launch in Q2 next year, which, if granted priority review, could accelerate market entry and strengthen the company's position in the competitive inhaled drug market.
See More
Latest Wall Street Ratings and Outlook
- Goldman Sachs Reiterates Nvidia Buy: Goldman Sachs anticipates a 'beat and raise' quarter for Nvidia ahead of its earnings report this month, focusing on the potential upside to its $1 trillion datacenter guidance, which could positively impact stock performance.
- JPMorgan Upgrades Freshpet: JPMorgan upgraded Freshpet from hold to buy following a first-quarter sales beat and guidance increase, expecting a rebound in share price as investors buy the dip after a 9% decline.
- Barclays Reiterates Microsoft Overweight: Barclays noted that Microsoft's story remains strong post-investor meetings, emphasizing management's focus on efficiency gains that are likely to enhance Azure growth and competitive positioning.
- Jefferies Upgrades Agilon Health: Jefferies highlighted improving visibility for Agilon Health, with supportive Medicare Advantage rates locked in, suggesting a favorable outlook that could attract investor interest moving forward.
See More
MannKind Partners with United Therapeutics for New Drug Development
- Drug Development Partnership: MannKind is collaborating with United Therapeutics to develop an inhaled version of Ralinepag, with MannKind supporting formulation and supply, potentially earning up to $35 million in milestone payments, highlighting the company's prospects in the pulmonary arterial hypertension market.
- Significant Stock Surge: MannKind's shares jumped over 30% on Wednesday, marking the largest single-day gain since February 2021 and breaking past the 100-day moving average for the first time in over two months, reflecting strong market interest in its drug progress.
- Innovative Drug Formulation: The company is developing a dry powder inhalation (DPI) version of Ralinepag, aiming for less frequent dosing; initial studies indicate that its oral form met primary endpoints in a Phase 3 trial, suggesting promising potential for the inhaled therapy.
- Shifting Market Sentiment: Retail sentiment for MannKind on Stocktwits shifted from neutral to bullish, with users expressing optimism about further stock price increases over the next two months, despite the stock's nearly 36% decline this year.
See More
MannKind and United Therapeutics Expand Collaboration Agreement
- Stock Surge: MannKind (MNKD) shares rose approximately 16% in premarket trading on Wednesday, reflecting positive market sentiment towards its newly expanded collaboration agreement with United Therapeutics (UTHR), indicating investor confidence in future growth potential.
- New Therapy Development: MannKind is developing a dry powder inhaler version of the drug ralinepag (MNKD-1501) as part of the expanded agreement with United Therapeutics, aimed at providing new treatment options for pulmonary arterial hypertension and enriching its product portfolio.
- Funding Support: Under the expanded agreement, MannKind received $5 million from UTHR last month to expedite the development of ralinepag DPI, which not only aids in shortening the time to market but also enhances the company's competitive position in the pulmonary disease treatment market.
- Future Revenue Potential: MannKind stands to gain $35 million in development milestone payments and 10% royalties on net sales of MNKD-1501, which will provide robust financial support for the company’s future performance, especially as it expands into new indications like interstitial lung disease and idiopathic pulmonary fibrosis.
See More
United Therapeutics Q1 Earnings Miss Expectations
- Earnings Performance: United Therapeutics reported a Q1 GAAP EPS of $5.82, missing expectations by $1.04, indicating a decline in profitability that may affect investor confidence.
- Revenue Decline: The company generated $781.5 million in revenue for Q1, a 1.6% year-over-year decrease that fell short of projections, reflecting weak market demand and potentially impacting future growth prospects.
- Market Reaction: The disappointing earnings report may lead investors to reassess their investment strategies regarding United Therapeutics, resulting in increased stock price volatility and affecting the company's performance in the capital markets.
- Future Outlook: Despite the current earnings miss, the company's prospects in the manufactured organs sector remain promising, and successful advancement of related projects could provide momentum for future performance recovery.
See More
MannKind Collaborates with United Therapeutics on Ralinepag DPI Development
- Collaboration Expansion: MannKind is developing a dry powder inhalation (DPI) formulation of ralinepag under an expanded licensing agreement with United Therapeutics from 2025, aiming to enhance treatment options for pulmonary arterial hypertension (PAH), which could significantly improve patient outcomes.
- Financial Backing: United Therapeutics made a $5 million payment to MannKind in April 2026 to expedite the development of ralinepag DPI, with MannKind eligible for up to $35 million in milestone payments and 10% royalties on net sales, thereby strengthening its financial position.
- Clinical Research Plans: MannKind is currently formulating ralinepag DPI for non-clinical studies and plans to conduct a phase 1 study in healthy volunteers to assess dosing and pharmacokinetic comparability with oral ralinepag tablets, which will inform pivotal studies in PAH patients.
- Market Potential: The long half-life of ralinepag may support once-daily dosing, and United Therapeutics plans to develop the product for pulmonary hypertension associated with interstitial lung disease, indicating broad future market applications for this therapy.
See More
United Therapeutics Q1 2026 Earnings Call Insights
- Clinical Trial Results: United Therapeutics highlighted significant outcomes from two Phase III trials in its Q1 earnings report, achieving a p-value of less than 0.0001, indicating substantial therapeutic potential in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH), which is expected to drive revenue growth from $3 billion to $4 billion.
- Revenue Performance: The company reported total revenue of $782 million for Q1 2026, facing challenges from severe winter weather and pharmacy operational issues that slowed starts; however, management remains confident in returning to sequential growth and sustaining double-digit growth in the near term.
- New Product Development: The introduction of the inhaled formulation of ralinepag (RALDPI) is anticipated to treat tens of thousands of patients across PAH, ILD, IPF, and PPF, further expanding market share and enhancing revenue potential.
- Regulatory Progress: Management plans to file a supplemental new drug application for IPF by the end of summer and expects a launch in Q2 next year, which, if granted priority review, could accelerate market entry and strengthen the company's position in the competitive inhaled drug market.
See More
Latest Wall Street Ratings and Outlook
- Goldman Sachs Reiterates Nvidia Buy: Goldman Sachs anticipates a 'beat and raise' quarter for Nvidia ahead of its earnings report this month, focusing on the potential upside to its $1 trillion datacenter guidance, which could positively impact stock performance.
- JPMorgan Upgrades Freshpet: JPMorgan upgraded Freshpet from hold to buy following a first-quarter sales beat and guidance increase, expecting a rebound in share price as investors buy the dip after a 9% decline.
- Barclays Reiterates Microsoft Overweight: Barclays noted that Microsoft's story remains strong post-investor meetings, emphasizing management's focus on efficiency gains that are likely to enhance Azure growth and competitive positioning.
- Jefferies Upgrades Agilon Health: Jefferies highlighted improving visibility for Agilon Health, with supportive Medicare Advantage rates locked in, suggesting a favorable outlook that could attract investor interest moving forward.
See More
MannKind Partners with United Therapeutics for New Drug Development
- Drug Development Partnership: MannKind is collaborating with United Therapeutics to develop an inhaled version of Ralinepag, with MannKind supporting formulation and supply, potentially earning up to $35 million in milestone payments, highlighting the company's prospects in the pulmonary arterial hypertension market.
- Significant Stock Surge: MannKind's shares jumped over 30% on Wednesday, marking the largest single-day gain since February 2021 and breaking past the 100-day moving average for the first time in over two months, reflecting strong market interest in its drug progress.
- Innovative Drug Formulation: The company is developing a dry powder inhalation (DPI) version of Ralinepag, aiming for less frequent dosing; initial studies indicate that its oral form met primary endpoints in a Phase 3 trial, suggesting promising potential for the inhaled therapy.
- Shifting Market Sentiment: Retail sentiment for MannKind on Stocktwits shifted from neutral to bullish, with users expressing optimism about further stock price increases over the next two months, despite the stock's nearly 36% decline this year.
See More
MannKind and United Therapeutics Expand Collaboration Agreement
- Stock Surge: MannKind (MNKD) shares rose approximately 16% in premarket trading on Wednesday, reflecting positive market sentiment towards its newly expanded collaboration agreement with United Therapeutics (UTHR), indicating investor confidence in future growth potential.
- New Therapy Development: MannKind is developing a dry powder inhaler version of the drug ralinepag (MNKD-1501) as part of the expanded agreement with United Therapeutics, aimed at providing new treatment options for pulmonary arterial hypertension and enriching its product portfolio.
- Funding Support: Under the expanded agreement, MannKind received $5 million from UTHR last month to expedite the development of ralinepag DPI, which not only aids in shortening the time to market but also enhances the company's competitive position in the pulmonary disease treatment market.
- Future Revenue Potential: MannKind stands to gain $35 million in development milestone payments and 10% royalties on net sales of MNKD-1501, which will provide robust financial support for the company’s future performance, especially as it expands into new indications like interstitial lung disease and idiopathic pulmonary fibrosis.
See More
United Therapeutics Q1 Earnings Miss Expectations
- Earnings Performance: United Therapeutics reported a Q1 GAAP EPS of $5.82, missing expectations by $1.04, indicating a decline in profitability that may affect investor confidence.
- Revenue Decline: The company generated $781.5 million in revenue for Q1, a 1.6% year-over-year decrease that fell short of projections, reflecting weak market demand and potentially impacting future growth prospects.
- Market Reaction: The disappointing earnings report may lead investors to reassess their investment strategies regarding United Therapeutics, resulting in increased stock price volatility and affecting the company's performance in the capital markets.
- Future Outlook: Despite the current earnings miss, the company's prospects in the manufactured organs sector remain promising, and successful advancement of related projects could provide momentum for future performance recovery.
See More
MannKind Collaborates with United Therapeutics on Ralinepag DPI Development
- Collaboration Expansion: MannKind is developing a dry powder inhalation (DPI) formulation of ralinepag under an expanded licensing agreement with United Therapeutics from 2025, aiming to enhance treatment options for pulmonary arterial hypertension (PAH), which could significantly improve patient outcomes.
- Financial Backing: United Therapeutics made a $5 million payment to MannKind in April 2026 to expedite the development of ralinepag DPI, with MannKind eligible for up to $35 million in milestone payments and 10% royalties on net sales, thereby strengthening its financial position.
- Clinical Research Plans: MannKind is currently formulating ralinepag DPI for non-clinical studies and plans to conduct a phase 1 study in healthy volunteers to assess dosing and pharmacokinetic comparability with oral ralinepag tablets, which will inform pivotal studies in PAH patients.
- Market Potential: The long half-life of ralinepag may support once-daily dosing, and United Therapeutics plans to develop the product for pulmonary hypertension associated with interstitial lung disease, indicating broad future market applications for this therapy.
See More
